Abstract
We studied whether a polygenic score for reduced kidney function developed from population-based studies was associated with adverse outcomes among persons with chronic kidney disease. The polygenic score was significantly associated with incident kidney failure, major adverse cardiovascular outcomes and overall mortality while adjusting for age, sex, and baseline eGFR: the hazard ratio for kidney failure over 6.5 years was 1.83 (95% CI 1.40-2.39) comparing those in the highest and lowest quartiles of the polygenic score. However, the significant associations of the polygenic score did not translate to improved outcome prediction in comparison to established risk equations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The GCKD study was funded by grants from the BMBF (grant number 01ER0804) and the KfH Foundation for Preventive Medicine and corporate sponsors (http://www.gckd.org). Genotyping in GCKD was supported by Bayer Pharma AG. We are grateful for the willingness of the patients to participate in the GCKD study. The enormous effort of the study personnel of the various regional centers is highly appreciated. We thank the large number of nephrologists who provide routine care for the patients and collaborate with the GCKD study. The GCKD Investigators are listed in the Supplementary Material.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The GCKD Study was registered in the national registry for clinical studies (DRKS 00003971). It recruited participants in nine sites and was approved by all local ethic committees (i.e.University of Erlangen-Nuernberg; University of Freiburg; RWTH Aachen University;Charite, University Medicine Berlin; Hannover Medical School; University of Heidelberg;University of Wuerzburg; Ludwig-Maximilians University of Muenchen; University of Jena).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* a list of the GCKD Investigators is included in Supplementary Information
Data Availability
Public posting of individual level participant data is not covered by the informed patient consent form. As stated in the patient consent form and approved by the Ethics Committees, a dataset containing pseudonyms can be obtained by collaborating scientists upon approval of a scientific project proposal by the steering committee of the GCKD study: https//:www.gckd.org. All data produced in the present study are available upon reasonable request to the authors.
